United States

Profile: Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

22 Nov 2017
Change (% chg)

¥-49 (-0.77%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's businesses include pharmaceutical business and other business. The Company's segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South America), China, Asia (South Korea, Taiwan, Hong Kong, India and ASEAN), EMEA (Europe, the Middle East, Africa and Oceania) and Consumer Healthcare Business-Japan. The Company offers products, which include Halaven, Aricept, Aloxi, Fycompa, Lenvima, Methycobal, BELVIQ, Pariet, LYRICA, HUMIRA, Lunesta, E5501/AKR-501, BAN2401, Chocola BB Products, E2609 and E2006. The Company's consumer healthcare brand containing Vitamin B is Chocola BB Products. The Company offers a range of products, including Chocola BB Plus, a Vitamin B2 preparation for rough skin and stomatitis, and nutritional supplements and energy drinks, which are available for healthcare needs.

Company Address

Eisai Co Ltd

Eisai Main Bldg., 4-6-10, Koishi
BUNKYO-KU   TKY   112-8088
P: +813.38173700
F: +813.38113305

Company Web Links